**Microrna-135A-5P promotes proliferation and metastasis of hepatocellular carcinoma cells via upregulation of FOXO1**

Tian Zhang¹, Lingling Guan², Xiaomeng Xie², Lixing Guo³, Dongjing Ni²*

¹Department of Pathology, Shiyan People’s Hospital of Bao’an District, China, 
²Department of Gastroenterology, The Fifth Affiliated Hospital of Jinan University (Shenhe People’s Hospital), China, ³Department of Oncology, The Fifth Affiliated Hospital of Jinan University (Shenhe People’s Hospital), China

Numerous studies have focused on microRNAs (miRNAs) in hepatocellular carcinoma (HCC). However, the specific role of miR-135a-5p in HCC has remained unclear. Thus, this study aimed to elucidate the role and mechanisms of action of miR-135a-5p in HCC. Transfected Huh-7 HCC cells were subjected to cell proliferation, apoptosis, migration, and invasion assays to investigate the role of miR-135a-5p and FOXO1 in modulating cellular functions. Additionally, tumor xenografts from nude mice were utilized in vivo to validate the in vitro findings. Downregulation of miR-135a-5p or upregulation of FOXO1 inhibited cell proliferation and metastasis of Huh-7 cells while promoting apoptosis. Conversely, upregulation of miR-135a-5p induced proliferation and metastasis of Huh-7 cells while suppressing apoptosis. Furthermore, FOXO1 was identified as a direct target of miR-135a-5p. Notably, downregulation of miR-135a-5p or upregulation of FOXO1 suppressed tumor growth in Huh-7 cells. Inhibition of miR-135a-5p impeded HCC cell proliferation and metastasis by upregulating FOXO1 expression.

Keywords: Hepatocellular carcinoma. MicroRNA-135a-5p. Transcription factor forkhead box O1. Proliferation. Metastasis.


INTRODUCTION

Hepatocellular carcinoma (HCC) presents a distinctive management challenge due to the high variability of its molecular phenotypes (Yang et al., 2020). The incidence of HCC has been steadily rising over the past thirty years and is projected to affect over a million individuals annually by 2025 (Renne et al., 2021). Hepatitis B and C viruses (HCV), host immunity, cellular mutations, and chronic inflammation are commonly believed to stimulate HCC (Zhang et al., 2022). Early diagnosis allows for treatment using locoregional therapies such as surgical resection, transarterial chemoembolization, radiofrequency ablation, or liver transplantation. Nevertheless, HCC is often diagnosed at a late stage with unresectable tumors, rendering these treatments ineffective (Chidambaramanathan-Reghupaty, Fisher, Sarkar, 2021). Therefore, there is an urgent need to explore novel treatment modalities for HCC.

Numerous studies have implicated microRNAs (miRNAs) in various aspects of HCC including occurrence, progression, drug resistance, and recurrence (Oura, Morishita, Masaki, 2020). Specific miRNAs such as miR-21a, miR-4262 (upregulated), and miR-98, miR-613 (downregulated) have been identified in HCC (Khan et al., 2022, Xu et al., 2018). Notably, miR-135a-5p-induced downregulation of tyrosine phosphatase receptor delta has been implicated as a trigger for HCV-related HCC (Van Renne et al., 2018). In addition, miR-135a-5p-activated krüppel-like factor-4 (KLF4) downregulation has been
associated with HCC cell metastasis and proliferation via transforming growth factor-β1 (Yao et al., 2016). Functional assays have revealed that exosomal miR-135a-5p stimulates HCC cell proliferation and chemotherapy resistance (Wei et al., 2021). The transcription factor forkhead box O1 (FOXO1) plays a pivotal role as a tumor suppressor, involved in apoptosis, DNA damage repair, oxidative stress response, and cell cycle regulation (Reyes et al., 2021). Impairment of FOXO1 has been linked to tumor stemness in HCC (Lin et al., 2019), and its suppression is partially associated with HCC pathogenesis (Chand et al., 2022, Yang et al., 2019). Interaction between miR-135a and FOXO1 in HCC has been evidenced by miR-135a promoting HCC cell invasion through targeting FOXO1 (Zeng et al., 2016). Furthermore, the miR-135a/FOXO1 axis is involved in hepatocarcinogenesis driven by hepatitis B X-interacting protein-mediated phosphoenolpyruvate carboxykinase repression (Shi et al., 2016). Collectively, the molecular mechanism of miR-135a-5p and its interactions with FOXO1 warrant further investigation. Hence, this study aimed to elucidate the mechanisms of action of miR-135a-5p and FOXO1 in HCC and to identify therapeutic targets for HCC.

**MATERIAL AND METHODS**

**Ethics statement**

This study for clinical samples was approved by the ethics committee of our hospital (approval number: 20200314). The signed informed consent was obtained from the patients involved, adhering to “Good Clinical Practice”. Animal experiments were reviewed and supervised by the Animal Ethics Association of our hospital (approval number: 20200722).

**HCC specimen collection**

Specimens were obtained from HCC patients who underwent surgical treatment at our hospital. The specimens, comprising 98 HCC tissues and 98 adjacent normal tissues (located 3 cm away from the foci) without malignant cells, were confirmed by pathology as HCC. Fresh specimens were collected during surgery, promptly frozen in liquid nitrogen, and stored at -80°C.

Among the 98 patients, 71 were male and 27 were female, with ages ranging from 24 to 73 years (median age, 51 years). Tumor differentiation grading revealed 23 cases of well-differentiated tumors and 75 cases of moderately and poorly differentiated tumors. Regarding tumor node metastasis staging, 65 cases were classified as stages I-II, and 33 cases as stages III-IV, following the standards of the International Union Against Cancer. Importantly, none of the patients had received radiotherapy or chemotherapy before undergoing surgery.

**Cell culture**

Human HCC cells Huh-7 (American Type Culture Collection, VA, USA) were cultured in DMEM containing 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 U/mL streptomycin (Gibco, Grand Island, NY, USA) with 5% CO₂ at 37 °C. The cells were passaged every 1-2 days, and experiments were conducted using cells in the logarithmic growth phase.

**Cell grouping**

The Huh-7 cells were divided into several groups, and the transfection treatments for each group are detailed in Table I. Oligonucleotides and plasmids used for transfection were sourced from GenePharma (Shanghai, China).

Huh-7 cells (2 × 10⁵ cells/well) were seeded in a 6-well plate and cultured at 37°C with 5% CO₂. Upon 60–70% confluence, the cells were transfected according to the guidelines for Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA).
Microrna-135A-5P promotes proliferation and metastasis of hepatocellular carcinoma cells via upregulation of FOXO1

**TABLE I - Transfection treatment of the cells in each group**

<table>
<thead>
<tr>
<th>Group</th>
<th>Transfection treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>inhibitor negative control (NC) group</td>
<td>Huh-7 cells transfected with miR-135a-5p inhibitor negative control</td>
</tr>
<tr>
<td>miR-135a-5p inhibitor group</td>
<td>Huh-7 cells transfected with miR-135a-5p inhibitor</td>
</tr>
<tr>
<td>mimic NC group</td>
<td>Huh-7 cells transfected miR-135a-5p mimic NC</td>
</tr>
<tr>
<td>miR-135a-5p mimic group</td>
<td>Huh-7 cells transfected with miR-135a-5p mimic</td>
</tr>
<tr>
<td>overexpression NC group</td>
<td>Huh-7 cells transfected with pcDNA empty vector</td>
</tr>
<tr>
<td>FOXO1 overexpression group</td>
<td>Huh-7 cells transfected with pcDNA-FOXO1 vector</td>
</tr>
<tr>
<td>miR-135a-5p inhibitor + siRNA-FOXO1 group</td>
<td>Huh-7 cells transfected with miR-135a-5p inhibitor and FOXO1 siRNA</td>
</tr>
</tbody>
</table>

Note: inhibitor negative control (NC) group is named as Inhibitor-Ctrl; miR-135a-5p inhibitor group is named as miR-135a-5p inhibitor; mimic NC group is named as mimic-Ctrl; miR-135a-5p mimic group is named as miR-135a-5p mimic; overexpression NC group is named as Oe-Ctrl; FOXO1 overexpression group is named as Oe-FOXO1; miR-135a-5p inhibitor + siRNA-FOXO1 group is named as miR-135a-5p inhibitor + si-FOXO1.

**RT-qPCR**

Total RNA was extracted from tissues and cells using TRIzol reagent (Invitrogen, Carlsbad, California, USA). For FOXO1, RT-qPCR was performed using the PrimeScript RT Reagent Kit (Takara) and SYBR Premix Ex Taq II (Takara). GAPDH served as the endogenous control. For miR-135a-5p, the Mir-X miR First-Strand Synthesis Kit (Takara) and SYBR Premix Ex Taq II (Takara) were utilized for RT-qPCR, with U6 used as a loading control. The thermocycling conditions were as follows: initial denaturation for 30 s at 95 °C, followed by 40 cycles of denaturation for 5 s at 95 °C, annealing for 30 s at 55 °C, and extension for 30 s at 72 °C. Primer sequences were designed and synthesized by BGI Tech (Beijing, China) (Table II). Subsequently, the melting curve was analyzed, and data were analyzed using the 2^-ΔΔCt method.

**TABLE II - Primer sequence in this study**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequence (5’-3’)</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-135a-5p</td>
<td>Forward: 5’-TATGGGCTTTTTATTTCTATGTGA-3’</td>
</tr>
<tr>
<td></td>
<td>Reverse: Universal primer</td>
</tr>
<tr>
<td>FOXO1</td>
<td>Forward: 5’-GCTGCATCCATGGAAAGACAAAGA-3’</td>
</tr>
<tr>
<td></td>
<td>Reverse: 5’-CGAGGGCCGAATGTACTCCAGTT-3’</td>
</tr>
<tr>
<td>U6</td>
<td>Forward: 5’-CTGCTCTCGGCAGACATATCTACT-3’</td>
</tr>
<tr>
<td></td>
<td>Reverse: 5’-ACGGCTTCACGAATTTGCGTGTC-3’</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Forward: 5’-TCAACGACCATTTGTGTCAGCTA-3’</td>
</tr>
<tr>
<td></td>
<td>Reverse: 5’-GCTGGGTGTCAGGAGGTTACTTACT-3’</td>
</tr>
</tbody>
</table>

Note: miR-135a-5p, microRNA-135a-5p; FOXO1, Transcription factor forkhead box O1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Western blot analysis

Protein extraction was performed using RIPA lysis buffer containing a protease inhibitor (Boster, Wuhan, China), and quantification was carried out using the bicinchoninic acid method. The proteins were then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene fluoride (PVDF) membrane. Subsequently, the PVDF membrane was blocked with a blocking solution containing 5% non-fat dry milk in PBST at room temperature for 1 hour. Primary antibodies FOXO1 (1:1000) and GAPDH (1:1000, Cell Signaling Technologies, Danvers, MA, USA) were applied overnight at 4 °C, followed by probing with the secondary antibody (1:5000, Cell Signaling Technologies) for 1 h at room temperature. Subsequently, enhanced chemiluminescence was added to the membrane for development, followed by exposure and photography. The resulting image was quantified using a gel image processing system (Quantity One), with GAPDH serving as the control. Protein expression levels of the target genes were determined as the ratio of the gray values.

Cell viability assay

The culture medium was discarded at 24, 48, and 72 h post-transfection. The cells were incubated with 100 μL of serum-free DMEM and 10 μL of CCK-8 solution (Dojindo Laboratories, Kumamoto, Japan) in darkness. After 2 h of incubation, the optical density (OD) was measured at 450 nm using a microplate reader.

Apoptosis by flow cytometry

Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) double staining and flow cytometry were performed to detect apoptosis. The cells were washed in phosphate-buffered saline (PBS) and resuspended in 200 μl binding buffer, followed by incubation with 5 μL of Annexin V-FITC and staining with 10 μL of PI solution. Subsequently, cell apoptosis was measured using a flow cytometer within 30 minutes. For result interpretation, Annexin V was plotted on the abscissa axis and PI on the vertical axis. The upper left quadrant indicated (Annexin V-FITC)/-PI-, signifying necrotic cells; the upper right quadrant denoted (Annexin V-FITC)/+PI+, revealing late-apoptotic cells; the lower right quadrant referred to (Annexin V-FITC)/-PI-, demonstrating early-apoptotic cells; while the lower left quadrant represented (Annexin V-FITC)/-PI-, indicating living cells. The apoptotic rate of cells was estimated as the percentage of late apoptotic cells, combined with the proportion of early apoptotic cells.

Cell invasion and migration assay

The cell invasion assay was implemented using Matrigel® (BD Biosciences, Franklin Lakes, NJ, USA)-coated Transwell chambers with an 8-μm pore polycarbonate membrane (Costar; Corning Incorporated, Corning, NY, USA) following the manufacturer’s instructions. Transfected cells were resuspended in FBS-free medium at a density of 2 × 10^4 cells/mL. The upper chamber was filled with 500 μL of the cell suspension, while the lower chamber contained medium with 10% FBS as the chemoattractant. Following a 48-hour incubation period, cells that had successfully invaded were fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, and enumerated under a light microscope. In the cell migration experiment, the upper chamber of the Transwell chamber was devoid of the Matrigel coating, while the remaining procedures were identical to those in the invasion experiment.

Tumor xenografts in nude mice

A total of 24 male BALB/c nude mice were randomly divided into four groups (n = 6): inhibitor-Ctrl, miR-135a-5p inhibitor, Oe-Ctrl, and Oe-FOXO1.

Cells in each group were detached and collected in centrifuge tubes to obtain cell suspensions (1 × 10^7 cells/mL) in PBS. Nude mice were disinfected routinely and injected with 0.2 mL of a single cell suspension subcutaneously into the armpit of the right forelimb. Following injection, the nude mice were kept under specific pathogen-free (SPF) conditions, and the formation of subcutaneous tumors was monitored continuously. On the 21st day post-injection, the nude mice were euthanized via carbon dioxide asphyxiation, and tumors were harvested. Tumors were measured using
a Vernier caliper, weighed using an electronic balance, and photographed. Tumor volume was calculated using the formula: \( (a) \times \text{width} \times (b)^2/2 \). Subsequently, the nude mice were euthanized, and the graft tumors were excised, collected, and fixed with 4% paraformaldehyde for 24 h. Following fixation, they underwent xylene and gradient alcohol dehydration, embedding in paraffin, and routine sectioning into 4 μm thickness for immunohistochemical staining, following the methodology described in the reference (Lu et al., 2018).

**Dual luciferase reporter gene assay**

The putative binding site of the 3'-untranslated region (UTR) of FOXO1 and miR-135a-5p was cloned into the pGL3 luciferase vector (Promega, Madison, WI, United States) to obtain FOXO1 wild type (Wt), and the binding site was mutated and then cloned into the pGL3 luciferase vector to obtain FOXO1 mutant (Mut). Huh-7 cells were seeded in a 24-well plate and co-transfected with FOXO1-Wt or FOXO1-Mut and miR-135a-5p mimic or mimic NC using Lipofectamine 2000 (Thermo Fisher Scientific). The corresponding luciferase activity was detected 48 h later using the manufacturer’s instructions (Promega Corporation, Madison, WI, USA).

**Statistical analysis**

All data were analyzed using Statistical software (IBM Corp. Armonk, NY, USA). Normal distribution of the observed data was confirmed using the Shapiro-Wilk W test, and results are presented as mean ± standard deviation. Differences between groups were assessed using unpaired (independent samples) or paired samples (paired data) with Student’s t-test or one-way analysis of variance (ANOVA), followed by Tukey’s post hoc test for multiple comparisons, where appropriate. Correlation analysis was conducted using Pearson’s test. A significance level of \( P < 0.05 \) was considered statistically significant.

**RESULTS**

**MiR-135a-5p is highly expressed and FOXO1 is poorly expressed in HCC tissues**

The expression levels of miR-135a-5p and FOXO1 were assessed in HCC tissues and adjacent normal tissues using RT-qPCR and western blot analyses (Figure 1A-D). Compared to adjacent normal tissues, miR-135a-5p expression was elevated while FOXO1 expression was reduced in HCC tissues (\( P < 0.05 \)). Further analysis using Pearson’s correlation revealed a negative correlation between the expression of miR-135a-5p and FOXO1 in HCC tissues (\( P < 0.05 \)) (Figure 1E). Additionally, miR-135a-5p expression exhibited significant associations with TNM stage and tumor differentiation (\( P < 0.05 \)), but not with the age and sex of HCC patients (\( P > 0.05 \)) (Figure 1F-I).
miR-135a-5p targets FOXO1 expression in HCC cells

Two publicly available algorithms, DIANA TOOLS and TargetScan, were utilized to identify potential targets of miR-135a-5p. TargetScan predicted FOXO1 as a potential target of miR-135a-5p (Figure 2A). Based on the predicted binding sites of miR-135a-5p, luciferase reporter plasmids containing FOXO1 3’ untranslated region (3’UTR) wild type (Wt) and mutant type (Mut) were generated (Figure 2B). A luciferase reporter assay was performed by co-transfecting the luciferase reporter plasmids with either the miR-135a-5p mimic or its control.

As depicted in Figure 2C, the overexpression of miR-135a-5p resulted in decreased luciferase activity driven by the Wt 3’UTR of FOXO1 (P < 0.05), while no significant alteration in luciferase activity driven by the Mut 3’UTR of FOXO1 was observed (P > 0.05).

Furthermore, the expression levels of miR-135a-5p and FOXO1 were detected in Huh-7 cells using RT-qPCR and western blot analysis (Figure 2D-F). In the miR-135a-5p mimic group, miR-135a-5p expression was upregulated compared to the NC group, while it was downregulated in the miR-135a-5p inhibitor group (P < 0.05). Correspondingly, the expression of
FOXO1 was significantly decreased in the miR-135a-5p mimic group and increased in the miR-135a-5p inhibitor group compared to the NC group (P < 0.05). Moreover, FOXO1 expression was notably elevated in the Oe-FOXO1 group compared to the Oe-Ctrl group (P < 0.05). Conversely, in the miR-135a-5p inhibitor group, FOXO1 expression was significantly reduced in the miR-135a-5p inhibitor + si-FOXO1 group (P < 0.05). These findings indicate that miR-135a-5p targets FOXO1 and inhibits its expression.

miR-135a-5p modulates FOXO1 to affect HCC cell proliferation and apoptosis

The proliferation of Huh-7 cells in each group was assessed using the CCK-8 assay (Figure 3A). Cell proliferation was significantly inhibited in the miR-135a-5p inhibitor and Oe-FOXO1 groups compared to the inhibitor-Ctrl and Oe-Ctrl groups (both P < 0.05). Conversely, cell proliferation was enhanced in the miR-135a-5p mimic group compared to the mimic-Ctrl group (P < 0.05). Additionally, cell proliferation was further increased in the miR-135a-5p inhibitor + si-FOXO1 group compared to the miR-135a-5p inhibitor group (all P < 0.05).

Cell apoptosis was assessed using Annexin V-FITC/PI double staining (Figure 3B,C). The results demonstrated that the apoptosis rate was significantly elevated in the miR-135a-5p inhibitor and Oe-FOXO1 groups compared to the inhibitor-Ctrl and Oe-Ctrl groups (both P < 0.05). Conversely, the rate of apoptosis was reduced in the miR-135a-5p mimic group compared to the mimic-Ctrl group (P < 0.05). Moreover, the apoptosis rate was lower in the miR-135a-5p inhibitor + si-FOXO1 group compared to the miR-135a-5p inhibitor group (P < 0.05).
FIGURE 3 - miR-135a-5p modulates FOXO1 to impact HCC cell proliferation and apoptosis. A. CCK-8 detection of the growth curve of Huh-7 cells in each group; B. Flow cytometry of Huh-7 cell apoptosis; C. Huh-7 cell apoptosis rate; * $P < 0.05$ compared with the Inhibitor-Ctrl group; # $P < 0.05$ compared with the mimic-Ctrl group; ^ $P < 0.05$ compared with the Oe-Ctrl group; & $P < 0.05$ compared with the miR-135a-5p inhibitor group.
microrna-135a-5p promotes proliferation and metastasis of hepatocellular carcinoma cells via upregulation of FOXO1

A transwell assay was employed to detect the migration and invasion abilities of Huh-7 cells in each group (Figure 4A-D). Compared to the Inhibitor-Ctrl and Oe-Ctrl groups, both the miR-135a-5p inhibitor and Oe-FOXO1 groups exhibited suppressed cell migration and invasion abilities (both $P < 0.05$). Conversely, the miR-135a-5p mimic group showed enhanced cell migration and invasion abilities compared to the mimic-Ctrl group ($P < 0.05$). Moreover, compared to the miR-135a-5p inhibitor group, the miR-135a-5p inhibitor + si-FOXO1 group displayed increased cell migration and invasion abilities ($P < 0.05$).

**FIGURE 4** - miR-135a-5p modulates FOXO1 to impact HCC cell invasion and migration. A-B. Transwell detection of migration ability of Huh-7 cells; C-D. Transwell detection of invasion ability of Huh-7 cells; * $P < 0.05$ compared with the Inhibitor-Ctrl group; # $P < 0.05$ compared with the mimic-Ctrl group; ^ $P < 0.05$ compared with the Oe-Ctrl group; & $P < 0.05$ compared with the miR-135a-5p inhibitor group.

miR-135a-5p downregulation and FOXO1 upregulation retard tumor growth in nude mice with HCC

*In vivo* xenografting of Huh-7 cells into nude mice was conducted to evaluate tumor growth status. The results revealed that (Figure 5A-C), compared to the Inhibitor-Ctrl and Oe-Ctrl groups, both tumor volume and weight were decreased in the miR-135a-5p inhibitor and Oe-FOXO1 groups (both $P < 0.05$). Immunohistochemistry was utilized to assess Ki-67 expression levels. The analysis demonstrated that Ki-67 expression levels were reduced in the miR-135a-5p inhibitor and Oe-FOXO1 groups compared to the Inhibitor-Ctrl and Oe-Ctrl groups (both $P < 0.05$) (Figure 5D).
Initially, we assessed the expression levels of miR-135a-5p and FOXO1 in HCC tissues, revealing elevated miR-135a-5p expression and decreased FOXO1 expression. Consistent with our observations, a previous study has shown that miR-135a-5p is a crucial regulator of HCC. However, further investigation is warranted into the miR-135a-5p/FOXO1 regulatory axis in HCC. This study was initiated to elucidate the mechanisms involving miR-135a-5p and FOXO1 in HCC and to conclude that downregulation of miR-135a-5p hampers HCC cell proliferation and metastasis by upregulating FOXO1 expression (Figure 6).

**FIGURE 5** - miR-135a-5p downregulation and FOXO1 upregulation retard tumor growth in nude mice with HCC. A. Tumors in nude mice; B. Tumor volume of nude mice; C. Tumor weight of nude mice; D. Ki-67 expression levels were determined by immunohistochemistry. *P < 0.05 compared with the Inhibitor-Ctrl group; ^P < 0.05 compared with the Oe-Ctrl group.

**DISCUSSION**

HCC is one of the predominant causes of cancer-related deaths and is the primary cause of death among patients with cirrhosis (Sidali et al., 2022). MiR-135a-5p is a crucial regulator of HCC (Lin et al., 2022). However, further investigation is warranted into the miR-135a-5p/FOXO1 regulatory axis in HCC. This study was initiated to elucidate the mechanisms involving miR-135a-5p and FOXO1 in HCC and to conclude that downregulation of miR-135a-5p hampers HCC cell proliferation and metastasis by upregulating FOXO1 expression (Figure 6).

**FIGURE 6** - The molecular mechanism involved in miR-135a-5p targets FOXO1 for HCC development.
study reported heightened miR-135a-5p expression in HCC tissues (Yao et al., 2016). Additionally, miR-135a expression is upregulated in HCC tissues, correlating with tumor staging, microvascular invasion, recurrence, and poor survival outcomes (Huang et al., 2017). In addition, miR-135a-5p expression is increased in HCC tissues compared to adjacent non-cancerous tissues (Wei et al., 2021). Our findings also revealed a close association between miR-135a-5p expression to tumor staging, recurrence, and reduced disease-free survival in HCC (Huang et al., 2017). Another study highlighted that tumors with elevated miR-135a expression exhibit more aggressive characteristics than those with low levels (Yan et al., 2016). All these studies validated the tumor-promoting effect of miR-135a-5p in HCC, suggesting its potential use as a therapeutic target. FOXO1 expression is exhibited that lower FOXO1 expression appears in HCC tissues and cells (Wang et al., 2019). Other articles have also indicated poorly expressed FOXO1 in HCC tissues and cells (Hu et al., 2022, Yang et al., 2019). These studies have validated the tumor-suppressive effect of FOXO1 in HCC. Nevertheless, the results of the present study are in agreement with these findings.

To explore the role of miR-135a-5p and FOXO1 in HCC cell progression, a series of assays were performed, demonstrating that downregulation of miR-135a-5p or upregulation of FOXO1 impeded HCC proliferation and metastasis while promoting cell apoptosis. Conversely, upregulation of miR-135a-5p induced HCC cell proliferation and metastasis while suppressing cell apoptosis. These findings underscore the critical roles of miR-135a-5p and FOXO1 in modulating HCC progression. Previous research has indicated a strong positive correlation between miR-135a expression and malignant behavior in HCC, suggesting its potential utility as a prognostic marker and therapeutic target (Huang et al., 2017). Functional assays have revealed that exosomal miR-135a-5p stimulates apoptosis, cell proliferation, and chemotherapy resistance in HCC (Wei et al., 2021). The roles of FOXO proteins, particularly FOXO1, in HCC have established a theoretical foundation for potential targeted treatment of HCC (Yang et al., 2021). The upregulation of FOXO1 is partially involved in the inhibition of HCC cell proliferation and apoptosis stimulation (Wang et al., 2019). Additionally, it has been previously documented that upregulation of FOXO impedes HCC cell viability and promotes cell apoptosis, and the influence of the miR-142-5p inhibitor on HCC cell viability and apoptosis is counteracted by the elevation of FOXO (Lou et al., 2017). FOXO1 inhibits hepatocarcinoma growth based on gain- and loss-of-function studies, and miR-9-5p/FOXO1/CPEB3 FFL promotes HCC cell growth and tumor progression both in animal and cellular assays (Hu et al., 2022). These findings are consistent with the results of the present study.

Subsequently, we identified FOXO1 as a direct target gene of miR-135a-5p. Consistent with our findings, previous studies have confirmed the targeting relationship between miR-135a-5p and FOXO1 in other diseases; FOXO1 has been validated as a target of miR-135a-5p, with miR-135a-5p negatively modulating FOXO1 expression (Wei et al., 2020; Xu et al., 2020). Additionally, there are publications demonstrating the targeting relationship between miR-135a and FOXO1, whereby miR-135a reduces FOXO1 expression by directly targeting the FOXO1 3’UTR (Shi et al., 2016; Zeng et al., 2016). In our study, rescue experiments revealed that downregulation of FOXO1 reversed the effects of downregulated miR-135a-5p on the malignant behavior of HCC. To further validate the roles of reduced miR-135a-5p and elevated FOXO1 in HCC, we conducted tumor xenograft experiments in nude mice in vivo. The results demonstrated that reduced miR-135a-5p or elevated FOXO1 impeded tumor growth in nude mice. Previous research has confirmed that miR-135a inhibition interferes with tumor growth in bladder cancer (Li et al., 2018), and the blockade of miR-135a-5p inhibits HCC tumor proliferation and metastasis in vivo (Yao et al., 2016). Additionally, nude mice with HCC have been shown to suppress tumor growth upon FOXO1 overexpression (Wang et al., 2019), and smaller xenograft tumors have been observed in nude mice injected with FOXO1 (Yang et al., 2019).

Furthermore, it is worth noting that miR-135a comprises both miR-135a-3p and miR-135a-5p, and we specifically focused on miR-135a-5p for its relevance...
Tian Zhang, Lingling Guan, Xiaomeng Xie, Lixing Guo, Dongjing Ni

Previous research has indicated that miR-135a promotes HCC cell migration and invasion, with a potential mechanism involving the suppression of FOXO1 (Zeng et al., 2016). Their study shed light on the crucial role of miR-135a in HCC and suggested the involvement of FOXO1 in its mechanism of action. However, our study took a more comprehensive approach by conducting assays on transfected HCC cell line Huh-7 cells to investigate the roles of both miR-135a-5p and FOXO1 in modulating cellular functions, including proliferation, apoptosis, migration, and invasion. Additionally, we employed tumor xenografts from nude mice in vivo to further validate the in vitro results. Our study underscores the significant contributions of both miR-135a and FOXO in HCC progression, with these effects also confirmed in animal experiments, representing the innovation of our study.

In summary, this study demonstrated that the inhibition of miR-135a-5p impedes HCC cell proliferation and metastasis through upregulation of FOXO1. These findings highlight the substantial role of the miR-135a-5p/FOXO1 regulatory axis in HCC and suggest a potential molecular therapeutic target for the disease. Nonetheless, larger cohort studies are warranted to explore novel therapies for HCC.

**REFERENCES**


Microrna-135A-5P promotes proliferation and metastasis of hepatocellular carcinoma cells via upregulation of FOXO1


Received for publication on 02nd November 2023
Accepted for publication on 14th March 2024